Fortrea Holdings Inc. (FTRE)
NASDAQ:FTRE
FTRE Stock Chart & Stats
$9.58
-$0.82(-4.27%)
At close: 4:00 PM EST
$9.58
-$0.82(-4.27%)
Day’s Range― - ―
52-Week Range$3.97 - $18.67
Previous CloseN/A
Volume188.47K
Average Volume (3M)1.80M
Market Cap
$895.73M
Enterprise Value$776.04M
Total Cash (Recent Filing)$174.60M
Total Debt (Recent Filing)$68.00M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
May 18, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding93,500,000
10 Day Avg. Volume2,205,510
30 Day Avg. Volume1,801,545
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.58
P/FCF Ratio17.82
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue0.28
Enterprise Value/Gross Profit1.74
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$15.86Price Target Upside65.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.69
Revenue Forecast (FY)$2.62B
Bulls Say, Bears Say
Bulls Say
Customer DemandAnalyst upgrade cites rising customer contract activity and more stable funding at large pharmaceutical clients, implying stronger demand for the company's services.
Management And StrategyNew leadership and visible progress executing a refreshed strategic plan are driving operational momentum and could amplify performance and deleveraging benefits.
MarginsAnalyst expects margins to improve as pass-through costs normalize and planned cost reductions take effect, which could boost profitability even if revenue softens.
Bears Say
Artificial Intelligence DisruptionMarket concerns about disruption from artificial intelligence have weighed on the share price and could continue to pressure investor sentiment if uncertainty persists.
Guidance RiskCompany guidance projects revenue below analyst and consensus expectations, creating uncertainty about growth prospects despite profitability guidance roughly matching models.
Industry Cyclicality And Drug PricingThe business remains exposed to a potential fade in the cyclic recovery of biopharma spending and renewed drug pricing uncertainty, which could reverse recent demand improvements.
Fortrea Holdings Inc. News
FTRE FAQ
What was Fortrea Holdings Inc.’s price range in the past 12 months?
Fortrea Holdings Inc. lowest stock price was $3.97 and its highest was $18.67 in the past 12 months.
What is Fortrea Holdings Inc.’s market cap?
Fortrea Holdings Inc.’s market cap is $895.73M.
When is Fortrea Holdings Inc.’s upcoming earnings report date?
Fortrea Holdings Inc.’s upcoming earnings report date is May 18, 2026 which is in 53 days.
How were Fortrea Holdings Inc.’s earnings last quarter?
Fortrea Holdings Inc. released its earnings results on Feb 26, 2026. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.169 by -$0.079.
Is Fortrea Holdings Inc. overvalued?
According to Wall Street analysts Fortrea Holdings Inc.’s price is currently Undervalued.
Does Fortrea Holdings Inc. pay dividends?
Fortrea Holdings Inc. does not currently pay dividends.
What is Fortrea Holdings Inc.’s EPS estimate?
Fortrea Holdings Inc.’s EPS estimate is 0.07.
How many shares outstanding does Fortrea Holdings Inc. have?
Fortrea Holdings Inc. has 93,500,000 shares outstanding.
What happened to Fortrea Holdings Inc.’s price movement after its last earnings report?
Fortrea Holdings Inc. reported an EPS of $0.09 in its last earnings report, missing expectations of $0.169. Following the earnings report the stock price went up 4.449%.
Which hedge fund is a major shareholder of Fortrea Holdings Inc.?
Currently, no hedge funds are holding shares in FTRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fortrea Holdings Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.86 (65.55% Upside)
$15.86 (65.55% Upside)
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.29%
12-Months-Change
Fundamentals
Return on Equity
-102.41%
Trailing 12-Months
Asset Growth
-24.13%
Trailing 12-Months
Company Description
Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
FTRE Company Deck
FTRE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced measurable operational and financial progress (positive cash generation in Q4, exceeded cost-savings targets, debt paydown, improved DSO, backlog and book-to-bill stabilization, AI investments and commercial wins) against persistent near-term revenue headwinds (Q4 revenue decline, FSP/pass-through variability, and 2026 revenue guidance implying a YoY decline). Management reiterated a multi‑pillar turnaround approach and provided a constructive outlook for improving EBITDA and cash flow across 2026, while cautioning the recovery may be uneven in the first half. Overall, the call reflected cautious optimism with concrete execution on cost and cash metrics but continued top-line risks that make recovery incremental.View all FTRE earnings summariesFTRE Stock 12 Month Forecast
Average Price Target
$15.86
▲(65.55% Upside)
Technical Analysis
Nektar Therapeutics
―
Fulcrum Therapeutics
―
Compass Therapeutics
―
Erasca
―
Aura Biosciences Inc
―
Ownership Overview
0.53% Insiders
19.50% Mutual Funds
23.04% Other Institutional Investors
22.15% Public Companies and
Individual Investors